Biotechnology Regulatory Environment and Clinical Trial Success: As a clinical-stage oncology biopharmaceutical company, Compass Therapeutics's performance is highly dependent on favorable clinical trial outcomes and subsequent regulatory approvals, such as the upcoming PFS/OS data for tovecimig expected in April 2026.

Funding and Capital Markets for Biotech: Clinical-stage biotech firms require significant R&D funding. Compass Therapeutics's ability to raise capital, demonstrated by its recent shelf registration for an equity offering, and its substantial cash runway into 2028, are crucial.

Competitive Landscape in Oncology: The oncology therapeutic market is highly competitive. The differentiation and effectiveness of Compass Therapeutics's pipeline products against existing and new treatments from competitors will determine its future market share and revenue potential.